"Agilent Labs’ expertise in molecular and computational biology is very important to our interdisciplinary research at the Reynolds Center," said Thomas Quertermous, M.D. (center), William G. Irwin Professor and Chief of Stanford’s Division of Cardiovascular Medicine. "We share the goal of understanding the basic mechanisms of heart disease - a leading cause of death - in order to improve its prevention, diagnosis and treatment.”

Also pictured are Laurakay Bruhn, Ph.D. (left), Project Manager, Molecular Diagnostics Department, Agilent Labs; and David Deng, Ph.D. (right), Research Scientist, Molecular Diagnostics Department, Agilent Labs.

Collaborations between Agilent Laboratories and leading research centers - such as the Donald W. Reynolds Cardiovascular Clinical Research Center at Stanford University - keep the Labs at the forefront of research and provide an in-depth understanding of emerging trends. The Reynolds Center and Agilent Labs are exploring use of Agilent’s microarrays in new biomedical research applications that may lead to future diagnostic applications.

Along with Agilent’s DNA microarrays and microarray systems, Agilent Labs is supplying proprietary computational tools and expertise in cardiovascular disease and information science. Using the Labs’ tools, the Reynolds Center can rapidly interpret data produced by tens of thousands of genes simultaneously as they interact to produce heart disease. Agilent’s ability to provide arrays with customized genetic content is critical in a research environment where the goal is to discover new genes of significance rather than to screen for known ones.